Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet

W. Lawrence Drew, Richard C. Miner, Gail I. Marousek, Sunwen Chou

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is undergoing clinical antiviral trials. Objectives: To assess the MBV sensitivity of CMV strains and isolates containing mutations that confer resistance to current antiviral drugs ganciclovir, cidofovir or foscarnet. Study design: Resistant clinical isolates and laboratory strains containing UL97 and or UL54 DNA polymerase mutations were tested for sensitivity to all four drugs by standard plaque reduction assay and a reporter-based yield reduction assay. Sensitive control strains were also tested. Results: Eleven CMV strains or isolates resistant to GCV, four resistant to FOS and two resistant to CDV, were all sensitive to MBV. These viruses represent four UL97 mutations and three UL54 DNA polymerase mutations. The laboratory derived UL97 L397R mutant was highly MBV-resistant but remained sensitive to the other three drugs. Conclusions: No cross-resistance has been detected between viruses resistant to MBV and those resistant to one or more of the current CMV antiviral drugs, consistent with differences in their mechanisms of action.

Original languageEnglish (US)
Pages (from-to)124-127
Number of pages4
JournalJournal of Clinical Virology
Volume37
Issue number2
DOIs
StatePublished - Oct 2006

Fingerprint

Foscarnet
Ganciclovir
Cytomegalovirus
Antiviral Agents
Mutation
DNA-Directed DNA Polymerase
Pharmaceutical Preparations
Viruses
maribavir
cidofovir
Clinical Trials

Keywords

  • Cidofovir
  • Cytomegalovirus
  • Drug resistance
  • Foscarnet
  • Ganciclovir
  • Maribavir

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. / Drew, W. Lawrence; Miner, Richard C.; Marousek, Gail I.; Chou, Sunwen.

In: Journal of Clinical Virology, Vol. 37, No. 2, 10.2006, p. 124-127.

Research output: Contribution to journalArticle

Drew, W. Lawrence ; Miner, Richard C. ; Marousek, Gail I. ; Chou, Sunwen. / Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. In: Journal of Clinical Virology. 2006 ; Vol. 37, No. 2. pp. 124-127.
@article{d60fb49c247f4bb4980347aae31c1606,
title = "Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet",
abstract = "Background: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is undergoing clinical antiviral trials. Objectives: To assess the MBV sensitivity of CMV strains and isolates containing mutations that confer resistance to current antiviral drugs ganciclovir, cidofovir or foscarnet. Study design: Resistant clinical isolates and laboratory strains containing UL97 and or UL54 DNA polymerase mutations were tested for sensitivity to all four drugs by standard plaque reduction assay and a reporter-based yield reduction assay. Sensitive control strains were also tested. Results: Eleven CMV strains or isolates resistant to GCV, four resistant to FOS and two resistant to CDV, were all sensitive to MBV. These viruses represent four UL97 mutations and three UL54 DNA polymerase mutations. The laboratory derived UL97 L397R mutant was highly MBV-resistant but remained sensitive to the other three drugs. Conclusions: No cross-resistance has been detected between viruses resistant to MBV and those resistant to one or more of the current CMV antiviral drugs, consistent with differences in their mechanisms of action.",
keywords = "Cidofovir, Cytomegalovirus, Drug resistance, Foscarnet, Ganciclovir, Maribavir",
author = "Drew, {W. Lawrence} and Miner, {Richard C.} and Marousek, {Gail I.} and Sunwen Chou",
year = "2006",
month = "10",
doi = "10.1016/j.jcv.2006.07.010",
language = "English (US)",
volume = "37",
pages = "124--127",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet

AU - Drew, W. Lawrence

AU - Miner, Richard C.

AU - Marousek, Gail I.

AU - Chou, Sunwen

PY - 2006/10

Y1 - 2006/10

N2 - Background: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is undergoing clinical antiviral trials. Objectives: To assess the MBV sensitivity of CMV strains and isolates containing mutations that confer resistance to current antiviral drugs ganciclovir, cidofovir or foscarnet. Study design: Resistant clinical isolates and laboratory strains containing UL97 and or UL54 DNA polymerase mutations were tested for sensitivity to all four drugs by standard plaque reduction assay and a reporter-based yield reduction assay. Sensitive control strains were also tested. Results: Eleven CMV strains or isolates resistant to GCV, four resistant to FOS and two resistant to CDV, were all sensitive to MBV. These viruses represent four UL97 mutations and three UL54 DNA polymerase mutations. The laboratory derived UL97 L397R mutant was highly MBV-resistant but remained sensitive to the other three drugs. Conclusions: No cross-resistance has been detected between viruses resistant to MBV and those resistant to one or more of the current CMV antiviral drugs, consistent with differences in their mechanisms of action.

AB - Background: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is undergoing clinical antiviral trials. Objectives: To assess the MBV sensitivity of CMV strains and isolates containing mutations that confer resistance to current antiviral drugs ganciclovir, cidofovir or foscarnet. Study design: Resistant clinical isolates and laboratory strains containing UL97 and or UL54 DNA polymerase mutations were tested for sensitivity to all four drugs by standard plaque reduction assay and a reporter-based yield reduction assay. Sensitive control strains were also tested. Results: Eleven CMV strains or isolates resistant to GCV, four resistant to FOS and two resistant to CDV, were all sensitive to MBV. These viruses represent four UL97 mutations and three UL54 DNA polymerase mutations. The laboratory derived UL97 L397R mutant was highly MBV-resistant but remained sensitive to the other three drugs. Conclusions: No cross-resistance has been detected between viruses resistant to MBV and those resistant to one or more of the current CMV antiviral drugs, consistent with differences in their mechanisms of action.

KW - Cidofovir

KW - Cytomegalovirus

KW - Drug resistance

KW - Foscarnet

KW - Ganciclovir

KW - Maribavir

UR - http://www.scopus.com/inward/record.url?scp=33748967780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748967780&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2006.07.010

DO - 10.1016/j.jcv.2006.07.010

M3 - Article

C2 - 16962820

AN - SCOPUS:33748967780

VL - 37

SP - 124

EP - 127

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 2

ER -